Why the study?
Does intranasal SK&F 21687 prevent upper respiratory illness in men challenged with rhinovirus type 44?
Population
20 men challenged with rhinovirus type 44
Comparison
Intranasal SK&F 21687 medication vs Placebo
Design
RCT
Authors
Loading...
Intranasal SK&F 21687 confers no benefit in rhinovirus challenge; confirms lack of efficacy and closes this prophylactic approach.
Does intranasal SK&F 21687 prevent upper respiratory illness in men challenged with rhinovirus type 44?
Intranasal SK&F 21687 failed to prevent upper respiratory illness in men experimentally challenged with rhinovirus type 44.
Togo et al. (1973) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: